A major leap in insulin innovation is here, straight from IIT Kanpur Prof. Sandeep Verma & Prof. S. Ganesh have developed next-gen thermostable human insulin analogs that resist heat, avoid fibrillation, and retain full biological activity — even in challenging storage conditions. 

Why it matters:

For millions of people with diabetes, daily insulin injections are non-negotiable. But insulin’s tendency to degrade under heat or during transport puts lives at risk — especially in resource-limited or tropical regions.

What’s the breakthrough?

The new analogs:

• Show prolonged thermal stability
• Resist fibrillation far longer than native insulin
• Preserve bioactivity in vitro, ex vivo, and in vivo
• Achieve added stability via π–π stacking & hydrogen bonding

Enter Stablin Biosciences — a biotech startup born from this innovation!

Now advancing toward TRL 6–7, the team is actively seeking funding for pre-clinical trials in higher animal models to push this life-saving solution toward reality.

Read the full research published in Nature Communications Chemistry: https://nature.com/articles/s42004-024-01241-z

A homegrown solution with global health impact — ensuring safe, stable insulin access anytime, anywhere. Proud moment for India’s med-tech ecosystem!